


Mouse Semaphorin 3A Antibody

Monoclonal Rat IgG₁ Clone # 1040525 Catalog Number: MAB109031

DESCRIPTION			
Species Reactivity	Mouse		
Specificity	Detects mouse Semaphorin 3A in direct ELISAs.		
Source	Monoclonal Rat IgG ₁ Clone # 1040525		
Purification	Protein A or G purified from hybridoma culture supernatant		
Immunogen	Chinese Hamster Ovary cell line CHO-derived mouse Semaphorin 3A protein Asn21-Lys747 Accession # O08665		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose.		

APPLICATIONS				
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.				
	Recommended Concentration	Sample		
Intracellular Staining by Flow Cytometry	0.25 μg/10 ⁶ cells	bEnd.3 mouse brain endothelial cell line		

DATA



Semaphorin 3A

Detection of Semaphorin 3A in Mouse bEnd.3 Cell Line by Flow Cytometry. Mouse bEnd.3 brain endothelial cell line was stained with Rat Anti-Mouse Semaphorin 3A Monoclonal Antibody (Catalog # MAB109031, filled histogram) or isotype control antibody (Catalog # MAB005, open histogram), followed by Phycoerythrin-conjugated Anti-Rat IgG F(ab')2Secondary Antibody (Catalog # F0105B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer (Catalog # FC005). Staining was performed using our Staining Intracellular Proteins protocol.

PREPARATION AND STORAGE			
Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.		
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.		
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.		



Mouse Semaphorin 3A Antibody

Monoclonal Rat IgG₁ Clone # 1040525 Catalog Number: MAB109031

BACKGROUND

Semaphorin 3A (Sema3A; previously sem D, sema III or collapsin) is one of six Class 3 secreted semaphorins which share \sim 40-50% amino acid (aa) identity (1-3). Class 3 semaphorins are potent chemorepellents that function in axon and/or vascular guidance during development (2, 3). The 772 aa mouse Sema3C contains a 20 aa signal sequence, an \sim 500 aa N-terminal Sema domain that forms a β -propeller structure similar to that found in integrin molecules, a PSI domain, a furin-type cleavage site, an Ig-like domain, and a C-terminal basic domain (3, 4). Covalent dimerization plus cleavage at the C-terminus are required for activity of class 3 semaphorins (5, 6). The 95 kDa mature mouse Sema3A shares at least 95% aa identity with human, rat, equine and canine Sema3A, and 90% and 86% aa identity with chick and zebrafish Sema3A, respectively. Type 3 semaphorins transduce signals through transmembrane plexins, either directly or by binding associated neuropilin receptors (3). Sema3A signaling is transduced by plexin A1-4, indirectly via neuropilin-1 (3). Sema3A activity is mediated by small GTPases that influence actin rearrangement and integrin activity (7-9). It is important in developmental organization of central and peripheral nerves, including those in heart, lung, kidneys, bones, teeth, and visual and olfactory systems (1, 2, 10, 11). Gradients of Sema3A repel axons, but attract dendrites (11, 12). Sema3A affect vasculogenesis by inhibiting integrin function and, with Sema3F, promoting apoptosis of endothelial cells (3, 9, 12). It is thought to suppress cancer-related angiogenesis (3). In the immune system, Sema3A influences T cell proliferation, migration, response to activation, and interactions with dendritic cells (7, 13). It negatively regulates platelet activation (14). Expression of Sema3A in relevant parts of the nervous system may be increased in Alzheimer's disease, multiple sclerosis, ischemia and schizophrenia (2).

References:

- 1. Puschel, A.W. et al. (1995) Neuron 14:941.
- 2. Roth, L. et al. (2009) Cell. Mol. Life Sci. 66:649.
- 3. Neufeld, G and O. Kessler (2008) Nat. Rev. Cancer 8:632.
- 4. Gherardi, E. et al. (2004) Curr. Opin. Struct. Biol. 14:669.
- 5. Adams, R. H. et al. (1997) EMBO J. 16:6077.
- 6. Klosterman, A. et al. (1998) J. Biol. Sci. 273:7326.
- 7. Lepelletier, Y. et al. (2006) Eur. J. Immunol. 36:1782.
- 8. Schlomann, U. et al. (2009) J. Cell Sci. 122:2034.
- 9. Serini, G. et al. (2003) Nature 424:391.
- 10. leda, M. et al. (2007) Nat. Med. 13:604.
- 11. Chen, G. et al. (2008) Nat. Neurosci. 11:36.
- 12. Guttmann-Raviv, N. et al. (2007) J. Biol Chem. 282:26294.
- 13. Lepelletier, Y. et al. (2007) Proc. Natl. Acad. Sci. USA 104:5545.
- 14. Kashiwagi, H. et al. (2005) Blood 106:913.